Document is current
Any future updates will be listed below
-
Authors
Aydillo, Teresa https://orcid.org/0000-0003-3086-1058
Rombauts, Alexander https://orcid.org/0000-0003-0227-5916
Stadlbauer, Daniel https://orcid.org/0000-0001-6792-7650
Aslam, Sadaf
Abelenda-Alonso, Gabriela
Escalera, Alba
Amanat, Fatima
Jiang, Kaijun
Krammer, Florian https://orcid.org/0000-0003-4121-776X
Carratala, Jordi https://orcid.org/0000-0003-3209-2563
García-Sastre, Adolfo https://orcid.org/0000-0002-6551-1827
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (75N93019C00051)
- License Information
-
More Information
Article History
Received: 5 January 2021
Accepted: 25 May 2021
First Online: 18 June 2021
Competing interests
: A.G.S. is inventor of patents owned by the Icahn School of Medicine at Mount Sinai in the field of influenza virus vaccines. The A.G.S. lab has received research funds from Avimex, GSK, and 7Hills to investigate novel influenza virus vaccines. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list F.K. as co-inventor. D.S. and F.A. are also listed on the serological assay patent application as co-inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. F.K. has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus, and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. The other authors declare no competing interests.
